alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                           1,355
<SECURITIES>                                         0
<RECEIVABLES>                                    4,565
<ALLOWANCES>                                     1,748
<INVENTORY>                                      3,637
<CURRENT-ASSETS>                                 9,461
<PP&E>                                           9,482
<DEPRECIATION>                                   3,360
<TOTAL-ASSETS>                                  15,721
<CURRENT-LIABILITIES>                           10,069
<BONDS>                                            339
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                      2,201
<COMMON>                                        36,355
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                    15,721
<SALES>                                          3,572
<TOTAL-REVENUES>                                 3,572
<CGS>                                            3,314
<TOTAL-COSTS>                                    3,314
<OTHER-EXPENSES>                                 2,808
<LOSS-PROVISION>                                   179
<INTEREST-EXPENSE>                                  42
<INCOME-PRETAX>                                 (2,622)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    (2,622)
<EPS-PRIMARY>                                    (4.16)
<EPS-DILUTED>                                    (4.16)
        

</TABLE>
§ 20.112 Voluntary drug experience reports submitted by physicians and hospitals. ( a ) A voluntary drug experience report to the Food and Drug Administration on FDA Form 3500 shall be handled in accordance with the rules established in § 20.111(c)(3)(iii).
( b ) If a person requests a copy of any such record relating to a specific individual or a specific incident, such request will be denied unless accompanied by the written consent to such disclosure of the person who submitted the report to the Food and Drug Administration and the individual who is the subject of the report.
[42 FR 15616, Mar. 22, 1977, as amended at 54 FR 9038, Mar. 3, 1989; 62 FR 52249, Oct. 7, 1997]
<PAGE> 52-53
Exhibit 24

                              February 20, 1996



Mr. R. G. Reherman
Mr. A. E. Goebel
Southern Indiana Gas and Electric Company
29 N.W. Fourth Street
Evansville, Indiana 47741

J. H. Byington, Jr., Esq.
Winthrop, Stimson, Putnam & Roberts
40 Wall Street
New York, New York 10005


Dear Gentlemen:

    SIGCORP, Inc. and Southern Indiana Gas and Electric
Company will each file an Annual Report on Form 10-K for the
fiscal year ended December 31, 1995 ("Form 10-K") before
April 1, 1996 which will be accompanied by certain exhibits.

    We hereby authorize you, or any one of you, to complete
said Forms 10-K and to remedy any deficiencies with respect
to said Forms 10-K by appropriate amendment or amendments;
and we hereby make, constitute and appoint each of you our
true and lawful attorney for each of us and in each of our
names, places and steads, both in our individual capacities
as directors and that of officers of SIGCORP, Inc. and
Southern Indiana Gas and Electric Company, to sign and cause
to be filed with the Securities and Exchange Commission said
Forms 10-K, any appropriate amendment or amendments thereto,
and any exhibits thereto.

    The undersigned, SIGCORP, Inc. and Southern Indiana Gas
and Electric Company, also authorize you and any one of you
to sign said Forms 10-K and any amendment or amendments
thereto on its behalf as attorney-in-fact for its respective
officers, and to file the same as aforesaid together with
exhibits.

                   Very truly yours,

                   SIGCORP, Inc. and
                   SOUTHERN INDIANA GAS AND ELECTRIC COMPANY

                   By (R. G. Reherman) 
                    R. G. Reherman, Chairman, President and
                        Chief Executive Officer




(Robert L. Koch II)           (Donald E. Smith)
Robert L. Koch II             Donald E. Smith

(Jerry A. Lamb)               (James S. Vinson)
Jerry A. Lamb                 James S. Vinson


(Donald A. Rausch)            (N. P. Wagner)
Donald A. Rausch              N. P. Wagner



(Ronald G. Reherman)          (A. E. Goebel)
Ronald G. Reherman            A. E. Goebel

(R. W. Shymanski)             (S. M. Kerney)
Richard W. Shymanski          S. M. Kerney
###### Editorial Note on Part 137

#### Editorial Note:

Nomenclature changes to part 137 appear at 63 FR 14035, Mar. 24, 1998.

#### § 137.215 Yellow corn flour.

Yellow corn flour conforms to the definition and standard of identity prescribed by § 137.211 for white corn flour except that cleaned yellow corn is used instead of clean white corn.
###### Editorial Note on Part 172

#### Editorial Note:

Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

#### § 172.755 Stearyl monoglyceridyl citrate.

The food additive stearyl monoglyceridyl citrate may be safely used in food in accordance with the following provisions:

(a) The additive is prepared by controlled chemical reaction of the following:

| Reactant | Limitations |
| --- | --- |
| Citric acid | |
| Monoglycerides of fatty acids | Prepared by the glycerolysis of edible fats and oils or derived from fatty acids conforming with § 172.860. |
| Stearyl alcohol | Derived from fatty acids conforming with § 172.860, or derived synthetically in conformity with § 172.864. |

(b) The additive stearyl monoglyceridyl citrate, produced as described under paragraph (a) of this section, meets the following specifications:

Acid number 40 to 52.

Total citric acid 15 to 18 percent.

Saponification number 215-255.

(c) The additive is used or intended for use as an emulsion stabilizer in or with shortenings containing emulsifiers.
Fourth Court of Appeals

San Antonio, Texas

January 25, 2023

No. 04-22-00814-CV

IN THE INTEREST OF A.A.A., a Child

From the 341st Judicial District Court, Webb County, Texas

Trial Court No. 2020-FLD-001240-D3

Honorable Selina Nava Mireles, Judge Presiding

ORDER

In accordance with this court’s opinion of this date, this appeal is DISMISSED FOR LACK 

OF JURISDICTION. All pending motions, including notifications of late record, are DENIED 

AS MOOT. Because appellant is indigent, no costs of this appeal are assessed. 

It is so ORDERED on January 25, 2023.

_____________________________

Luz Elena D. Chapa, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 25th day of January, 2023.

_____________________________

Michael A. Cruz, Clerk of Court
##### 



EXHIBIT 99.1

WFS FINANCIAL INC

CERTIFICATION OF CEO AND CFO

In connection with the Annual Report of WFS Financial Inc (the Company) on
Form 10-K for the period ending December 31, 2002 as filed with the
Securities and Exchange Commission on the date hereof (the Report), the
undersigned Chief Executive Officer and Chief Financial Officer of the
Company, hereby certify, to the best of their knowledge and belief and
pursuant to 18 U.S.C., Chapter 63, Section 1350, as adopted pursuant to
Section 906 of the SarbanesOxley Act of 2002, that:



| | (1) |  | The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities and Exchange Act of 1934; and                          
| | --- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------
|
| | (2) |  | The information contained in the Report fairly presents, in
all material respects, the financial condition and result of
operations of the Company.

The foregoing Certification is incorporated solely for purposes of complying
the provisions of Section 906 of the Sarbanes-Oxley Act and is not intended to
be used for any other purpose.

WFS FINANCIAL INC

|                                                                                                                                                                        | 
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------- | 
|/s/  THOMAS A. WOLFE

Thomas A. Wolfe
President and Chief Executive Officer                                                                                             | 
|                                                                                                                                                                       
|                                                                                                                                                                       
|/s/  LEE A. WHATCOTT

Lee A. Whatcott
Senior Executive Vice President,
Chief Financial Officer and
Chief Operating Officer
(Principal Financial and Accounting Officer) |
§ 145.131 Artificially sweetened canned figs. ( a ) Artificially sweetened canned figs is the food which conforms to the definition and standard of identity prescribed for canned figs by § 145.130, except that in lieu of a packing medium specified in § 145.130(c), the packing medium used is water artificially sweetened with saccharin, sodium saccharin, or a combination of both. Such packing medium may be thickened with pectin and may contain any mixture of any edible organic salt or salts and any edible organic acid or acids as a flavor-enhancing agent, in a quantity not more than is reasonably required for that purpose.
( b ) ( 1 ) The specified name of the food is “artificially sweetened ______”, the blank being filled in with the name prescribed by § 145.130 for canned figs having the same optional fig ingredient.
( 2 ) The artificially sweetened food is subject to the requirements for label statement of ingredients used, as prescribed for canned figs by § 145.130. If the packing medium is thickened with pectin, the label shall bear the statement “thickened with pectin”. When any organic salt or acid or any mixture of two or more of these is added, the label shall bear the common or usual name of each such ingredient.
[42 FR 14414, Mar. 15, 1977, as amended at 58 FR 2880, Jan. 6, 1993]
# C_2019232EN.01000401.xml

| 10.7.2019 | EN | Official Journal of the European Union | C 232/4 |
| --- | --- | --- | --- |

10.7.2019

EN

Official Journal of the European Union

C 232/4

---

COUNCIL DECISION

of 8 July 2019

appointing one member of the Management Board of the European Agency for Safety and Health at Work (EU-OSHA) for Hungary

(2019/C 232/03)

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) 2019/126 of the European Parliament and of the Council of 16 January 2019 establishing the European Agency for Safety and Health at Work (EU-OSHA), and repealing Council Regulation (EC) No 2062/94 (1), and in particular Article 4 thereof,

Having regard to the list of candidates submitted to the Council by the Governments of the Member States and by the employees' and the employers' organisations,

Having regard to the lists of members and alternate members of the Advisory Committee on Safety and Health at Work,

Whereas:

| (1) | By its Decision of 9 April 2019 (2), the Council appointed the members and alternate members of the Management Board of the European Agency for Safety and Health at Work for the period from 1 April 2019 to 31 March 2023. |
| --- | --- |

(1)

By its Decision of 9 April 2019 (2), the Council appointed the members and alternate members of the Management Board of the European Agency for Safety and Health at Work for the period from 1 April 2019 to 31 March 2023.

| (2) | The employers' organisation BusinessEurope has submitted a nomination for one post to be filled, |
| --- | --- |

(2)

The employers' organisation BusinessEurope has submitted a nomination for one post to be filled,

HAS ADOPTED THIS DECISION:

Article 1

The following is appointed a member of the Management Board of the European Agency for Safety and Health at Work (EU-OSHA) for the period ending on 31 March 2023:

REPRESENTATIVES OF EMPLOYERS' ORGANISATIONS

| Country | Member | Alternate member |
| --- | --- | --- |
| Hungary | Ms Judit H. NAGY | |

Country

Member

Alternate member

Hungary

Ms Judit H. NAGY

Article 2

The Council shall appoint the members and alternate members not yet nominated at a later date.

Article 3

This Decision shall enter into force on the date of its adoption.

Done at 8 July 2019.

For the Council

The President

A.-K. PEKONEN

---

(1)  OJ L 30, 31.1.2019, p. 58.

1

(2)  OJ C 135, 11.4.2019, p. 7.

2

---
### SERVED : JANUAR Y 24 , ZUIZ ');ZPARTIviENTO F i'lANSPORTATIO N :':CKtTO^ERATiGN S m JAN :? 5 ARMi 2



### U.S . DEPARTMEN T O FTRANSPORTATIO N

OFFIC Eo r

HEARING S WASHINGTON , D C APPLICATIO N O F SU N QUES T EXECUTIV EAI RCHARTER , INC . For fee s an dexpense s under

th e Equa l Acces s to Justic e Act FDMSNo . FAA-20n-129 4 ORDE R O N APPLICANT' S BRIE F Su n Ques t Executiv e Ai rCharter , Inc . ("th e Applicant" ) has file d a n "Applicatio n fo rA n Awar d o f Attorne yFee s an d Othe rExpense s Pursuan t t o th e Equa l Acces s t o lustic e Ac t (EAjA), " tri^Eerin g thi s proceeding . Th e matte rwa s assigne d t o th e undersigne d b yNotic e date d |anuar y17 , 2012 . I t wil l b e decide d unde rth e EAJ A provisions , 5 U.S.C . §504 , an d implementin g regulation s 1 4 C.F.R . §14 . Complainan t Federa l Aviatio n Administratio n ha s alread yfile d a brie f i n opposition . Th e Applican t wil l hav e a n opportunit yt o respond . WHEREUPON , i t i s ORDERE D a s follows : Applican t Su n Ques t Executiv e Ai rCharter , Inc . shal l fil e a brie f supportin g it s Applicatio n n o late rtha n th e clos e o f busines s o n Februar y 10,2012 .Administrativ e La wJudg e

Attachmen t - Servic e Lis tFA A Docket No . CP08WP000 4 (Civi l Penalt

y Action ) SERVIC E LIS T ORIGINA L& ON ECOP Y Federa l Aviatio n Administratio n 80 0 Independenc e Avenue , S.W . Washington , DC 2059 1 Attention : Hearin g Dockei Clerk , AGC-430 ,

Wilbu r Wrighi Building—Suit e 2WI000 ' ON ECOP Y Sun Ques t Executiv e Air

Charter , Inc . Attn : Mar k Chiulc s Smith , Chie f

Pilo l 743 6 Hayvcnhurs t

Ave . VanNuys , C

A 9140 6 Arthur Wasscrman , Esq . La w Office s o

f Wasserman & Mille r 1638 0 Rcsco e Blvd. , Suite 120 VanNuy.s , C

A 91406-122 1 TEL : (818)895-823 4 FAX ; (818 ) 895-067 5 Naom i Tsuda , Regional Counse l Federal Aviatio n Administratio n Offic e o f th e Regional Counse l Wcsteni-Pacifi c Region . AWP- 7 P.O . Bo x 9200 7 Lo s Angeles , C

A 90009-200 7 TEL : (310)725-710 1 FAX ; (310)725-681 6 Th e Honorabl e RichardC . Goodwi n Adniinislraliv e La

w Judg e Offic e o f Hearings , M-2 0 U.S . Department

of Transportatio n 1200 New Jerse y Avenue , S.E . Eas t Building , Groun d Floo r Roo m El2-32 0 Washington , D C 2059 0 TEL : Attorney-Adviso r

(202 ) 366-2139 ; Legal Assistan t 6-51 2 FAX : (202)366-753 6

' Service wa

s h y U.S . Mail . Fo

r servic e i n perso n o i b y expeditedcourier, us

e th e fdUowini ; address : Federa l Avialio n Adminislratitm . 60

0 hidependence Avenue , S.W. , Wilbu r Wiigh l Building—Suil

e 2W10nO . Washinclon . D C 20591 ; Aiientiun ; Hearin g Docke t Clerk, AG

C 430 .
§ 182.1500 Monoammonium glutamate. ( a ) *Product.* Monoammonium glutamate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing practice.
§ 745.115 IRB Records. ( a ) An institution, or when appropriate an IRB, shall prepare and maintain adequate documentation of IRB activities, including the following: ( 1 ) Copies of all research proposals reviewed, scientific evaluations, if any, that accompany the proposals, approved sample consent forms, progress reports submitted by investigators, and reports of injuries to subjects.
( 2 ) Minutes of IRB meetings, which shall be in sufficient detail to show attendance at the meetings; actions taken by the IRB; the vote on these actions including the number of members voting for, against, and abstaining; the basis for requiring changes in or disapproving research; and a written summary of the discussion of controverted issues and their resolution.
( 3 ) Records of continuing review activities, including the rationale for conducting continuing review of research that otherwise would not require continuing review as described in § 745.109(f)(1).
( 4 ) Copies of all correspondence between the IRB and the investigators.
( 5 ) A list of IRB members in the same detail as described in § 745.108(a)(2).
( 6 ) Written procedures for the IRB in the same detail as described in § 745.108(a)(3) and (4).
( 7 ) Statements of significant new findings provided to subjects, as required by § 745.116(c)(5).
( 8 ) The rationale for an expedited reviewer's determination under § 745.110(b)(1)(i) that research appearing on the expedited review list described in § 745.110(a) is more than minimal risk.
( 9 ) Documentation specifying the responsibilities that an institution and an organization operating an IRB each will undertake to ensure compliance with the requirements of this policy, as described in § 745.103(e).
( b ) The records required by this policy shall be retained for at least 3 years, and records relating to research that is conducted shall be retained for at least 3 years after completion of the research. The institution or IRB may maintain the records in printed form, or electronically. All records shall be accessible for inspection and copying by authorized representatives of the Federal department or agency at reasonable times and in a reasonable manner.
(Approved by the Office of Management and Budget under Control Number 0990-0260)
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of State

          - [Public Notice Number: 6372]

The U.S. Advisory Commission on Public Diplomacy has rescheduled its public meeting to March 15, 2010 from 9 a.m. to 11 a.m. in the conference room of the International Foundation for Electoral Systems (IFES) located at 1850 K Street, NW., Fifth Floor, Washington, DC 20006. This will replace the previously scheduled February 11 meeting (canceled due to inclement weather) at the same location.

The Commissioners will discuss public diplomacy issues, including interagency collaboration in advancing U.S. government public diplomacy efforts.

The Commission is a bipartisan panel created by Congress in 1948 to assess public diplomacy policies and programs of the U.S. government and of publicly funded nongovernmental organizations. The Commission reports its findings and recommendations to the President, the Congress, the Secretary of State, and the American people.

                    The public may attend this meeting as seating capacity allows. To attend this meeting and for further information, please contact Carl Chan at (202) 632–2823; e-mail:                     *chanck@state.gov.*                     Any member of the public requesting reasonable accommodation at this meeting should contact Mr. Chan prior to March 8th. Requests received after that date will be considered, but might not be possible to fulfill.                

Dated: February 16, 2010.

Carl Chan,

Executive Director, ACPD.

[FR Doc. 2010–3563 Filed 2–22–10; 8:45 am]

BILLING CODE 4710–11–P
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.45 Inactive status. ( a ) If no subjects are entered into clinical studies for a period of 2 years or more under an IND, or if all investigations under an IND remain on clinical hold for 1 year or more, the IND may be placed by FDA on inactive status. This action may be taken by FDA either on request of the sponsor or on FDA's own initiative. If FDA seeks to act on its own initiative under this section, it shall first notify the sponsor in writing of the proposed inactive status. Upon receipt of such notification, the sponsor shall have 30 days to respond as to why the IND should continue to remain active.
( b ) If an IND is placed on inactive status, all investigators shall be so notified and all stocks of the drug shall be returned or otherwise disposed of in accordance with § 312.59.
( c ) A sponsor is not required to submit annual reports to an IND on inactive status. An inactive IND is, however, still in effect for purposes of the public disclosure of data and information under § 312.130.
( d ) A sponsor who intends to resume clinical investigation under an IND placed on inactive status shall submit a protocol amendment under § 312.30 containing the proposed general investigational plan for the coming year and appropriate protocols. If the protocol amendment relies on information previously submitted, the plan shall reference such information. Additional information supporting the proposed investigation, if any, shall be submitted in an information amendment. Notwithstanding the provisions of § 312.30, clinical investigations under an IND on inactive status may only resume (1) 30 days after FDA receives the protocol amendment, unless FDA notifies the sponsor that the investigations described in the amendment are subject to a clinical hold under § 312.42, or (2) on earlier notification by FDA that the clinical investigations described in the protocol amendment may begin.
( e ) An IND that remains on inactive status for 5 years or more may be terminated under § 312.44.
[52 FR 8831, Mar. 19, 1987, as amended at 52 FR 23031, June 17, 1987; 67 FR 9586, Mar. 4, 2002]